Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium ferentiated into striated muscle cells in vivo and improved myocardial function (11) . Hematopoietic stem cells were shown to induce neoangiogenesis associated with improved cardiac function in an experimental myocardial infarction (9, 18) . However, increasing controversy exists regarding the ability of bone marrow-derived cells, including bone marrow mesenchymal stem cells (MSCs), to transdifferentiate into cardiac cells (4, 13, 15) with the risk for unwanted differentiation toward fibroblasts (31) or calcifications (32) after injections into the infarcted myocardium. Consequently, the search for novel strategies of coaxing the cells toward a cardiac lineage has been recommended (6, 16) . Previous studies have used a DNA demethylating chemical compound, 5Ј-azacytidine, that induces uncontrolled myogenic specification by random demethylation (29, 30) . Note that, during embryonic development, signals emanating from adjacent endoderm and ectoderm, such as bone morphogenetic protein (BMP)-2/4, FGF, and IGF, as well as direct cell-cell interactions through specific extracellular matrix (ECM) are required for the specification and stabilization of the mesoderm to form a cardiac field (1, 3, 7, 26) . Likewise, the majority of experimental studies use small rodent models of myocardial infarction, and data in large animal models closer to the clinical situation are scarce. Therefore, we tested the primary hypothesis that growth factors involved in early cardiomyogenesis may drive adult MSCs toward the cardiomyogenic cell lineage in vitro. Second, using a dog model of chronic myocardial infarction, we explored the possibility that direct myocardial injection of growth factor-treated cells is associated with beneficial effects on biological and functional regeneration of chronically infarcted myocardium.
METHODS

Animals and bone marrow collection.
A total of 30 dogs (15-45 kg) were used (Harlan). The study was approved by the Ethical Committee for the Animal Research of the Louvain Medical School, Brussels, and the Faculty of Medicine, Free University of Brussels, Belgium. The myocardial infarction was caused by ligation of the coronary artery (left circumflex, n ϭ 25; left anterior descending artery n ϭ 5). Care was taken to ligate all visible epicardial collaterals. Bone marrow (15-20 ml) was collected from the anterior iliac crest into a syringe flushed with heparin. The sample was treated with a mix (1:1) of DMSO and hydroxyethyl starch solution (6%/6% final concentration) and frozen at Ϫ80°C until further processing.
Isolation and treatment of human and dog MSCs. After being thawed, marrow was plated onto T75 collagen-treated culture flasks in standard growth media to remove nonadherent cells. The plasticattached MSCs were culture expanded for 3 wk with media containing DMEM (Invitrogen), 20% fetal bovine serum (Hyclocene), 100 M L-ascorbic acid (Sigma Aldrich), 5 mg/ml human leukemia inhibitory factor (LIF, Sigma Aldrich), and 20 nM dexamethasone (Sigma Aldrich). After expansion, in the differentiation medium, LIF was removed, FBS was reduced to 2%, and cardiac differentiation was induced by adding the following cardiomyogenic growth factors for 6 days: 50 ng/ml basic FGF (R&D systems), 2.5-25 ng/ml BMP-2 (R&D systems), and 2 ng/ml insulin-like growth factor 1 (R&D systems). Cardiomyogenic specification of human cells was confirmed by immunohistochemistry. After treatment, predifferentiated dog cells were labeled with 1 M 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate (DiI) and frozen until injection. The karyotyping of the stem cells was performed before and after the growth factor treatment. Before injections, cells were washed using the culture medium and 1% PBS.
Experimental protocol. Pretreated autologous dog cells were injected directly into the infarcted myocardium at open thorax surgery. Before the cell injections, left ventricular (LV) dysfunction was documented as stable in all dogs at two consecutive echocardiography studies over the 3-wk period. Dogs were randomized into groups of animals receiving biologically treated (group A) and untreated (group B) MSCs on 2:1 ratio. In group A dogs, eight pilot animals receiving Ͻ20 ϫ 10 6 cells were killed at 1, 2, and 4 wk for the histological analysis without functional follow-up. Seven animals received 147 Ϯ 96 ϫ 10 6 pretreated MSCs and were followed by echocardiography up to 12 wk. In control group B, all animals underwent myocardial injections of only culture-expanded MSCs without growth factor treatment. Two pilot dogs were killed at 2 wk after the cell injection for the histological analysis without functional follow-up. Of the five animals receiving culture-expanded MSCs without treatment with cardiomyogenic growth factors (168 Ϯ 24 ϫ 10 6 cells), one died within 24 h after the cell injection and four underwent follow-up at 12 wk with echocardiography similar to that of group A animals. Five additional dogs in group A and three in group B underwent injections for quantitative histological analyses of cardiomyogenic conversion 1 mo after cell injection. To inhibit apoptotic cell death, a caspase-8 inhibitor, zVAD (5 M), was added to the cell suspension before cell injections in all animals of both groups. At 12-wk follow-up, animals were killed, the hearts were removed, and the infarct area was dissected into several samples and snap frozen in optimal cutting temperature (OCT) compound (Tissue-Tek, Sakura, Japan) until further histological analyses.
Immunohistochemistry. Isolated MSCs were plated onto collagencoated four-well glass chamber slides in differentiation media. Cells were fixed in ice-cold methanol, blocked in 2% BSA/PBS, and analyzed by immunofluorescence. Heart tissue sections were examined for DiI-positive cells under the fluorescent microscope. were used in each staining. Alexa Fluor 488 secondary antibody and DiI were purchased from Molecular Probes. Confocal microscopy was performed to confirm colocalization of the DiI and myocardial markers. The proportion of DiI-labeled cells colocalizing with cardiac MHC was expressed as a percentage of cells per square millimeter in analyzed tissue sections.
Echocardiography. Echocardiography was performed in awake animals from the parasternal short axis. Images were obtained at the basal LV just beyond the mitral valve, at the level of the midpapillary muscle and at the apical level. M-mode echocardiograms were recorded at the level of the infarcted myocardium. Images were digitally stored and analyzed off-line by an experienced blinded echocardiographer. Area (from two-dimensional) and fractional (from M-mode) shortenings were calculated from these data. The %wall thickening of the dysfunctional myocardium was calculated from the average of three consecutive beats. Wall motion score index was calculated using the 16-segment model. Baseline and follow-up echocardiograms were reviewed by a panel of blinded echocardiographers.
Statistical analysis. Data are expressed as means Ϯ SE. ANOVA for repeated measurements was used to test the differences in LV function over the follow-up period when appropriate. Student's paired and unpaired t-tests or Mann-Whitney test were used for appropriate comparisons. Statistical significance was set at Ͻ0.05 level.
RESULTS
Ex vivo cardiac specification of human bone marrow MSCs with cardiomyogenic growth factors.
We first tested the hypothesis that biological growth factors can induce MSCs to express cardiomyogenic-specific markers ex vivo. Canine MSCs exhibited a fibroblastic morphology similar to that of MSCs isolated from other species, such as mouse, rat, and human. Human MSCs isolated from bone marrow in a similar manner were positive for c-kit and CD13 and negative for CD34, CD45, and CD49 ( Fig. 1) , suggesting the presence of a homogenous MSC population.
Following growth factor addition, pretreated MSCs showed a uniform expression of MEF-2, GATA-4, and Nkx-2.5 and cardiac transcription factors (Fig. 2) . Expression of MEF-2 and GATA-4 were nuclear localized, whereas Nkx-2.5 expression was found perinuclear and also in the cytoplasm. Growth factor treatment also induced the expression of desmin, an intermediate filament expressed in cardiac and skeletal muscle progenitor cells. Treated MSCs did not fully differentiate into contracting cardiomyocyte, nor did they express MF-20, a marker for MHC in fully differentiated muscle cells. Treated MSCs were also expressing in a low proportion early endothelial cell marker CD14 (12%). Expression of the leukocyte alkaline phosphatase, used as an osteogenic marker, was very faint or not induced at all after growth factor treatment. No expression of early cardiac markers has been observed in untreated, culture-expanded MSCs. Taken together, these results indicate that treatment of MSCs with biological growth factors induced predominantly the expression of genes specific for cardiomyogenic progenitor cells. Of note, culture expansion and differentiation resulted in no changes in the karyotypes of the MSCs (data not shown).
Histological analysis after cell injection. Next, we examined the potential of the specified autologous MSCs to undergo further cardiac differentiation after injection in a chronic dog model of infarcted myocardium due to permanent coronary ligation. Injections were performed at least 8 wk after myocardial infarction when stable LV regional dysfunction was documented by echocardiography. Heart sections that contained DiI-labeled cells were analyzed for the expression of cardiac and muscle specific markers at 2 wk, 4 wk, and 12 wk after injection (Fig. 3) . At 2 wk after injection (Fig. 3, panel I ), DiI-labeled cells were positive for adult sarcomeric myosin. At 4 and 12 wk after myocardial injections of pretreated MSCs (Fig. 3, panels II-IV) , DiI-labeled prespecified cells colocalized with cardiac-specific myosin or troponin I consistent with further differentiation into the cardiac myocyte-like cells. The presence of newly differentiated cardiomyocyte-like cells was observed within the fibrotic area of the infarction and parallel to the neighboring myocytes. Confocal microscopy (Figs. 4 and 5) corroborated colocalization of injected cells with troponin I or cardiac myosin and documented that morphology of transformed cells was similar to neighboring cardiac myocytes including the presence of striations (Fig. 5, top) . Furthermore, injected cells expressed connexin 43, being consistent with the integration in the host tissue (Fig. 5, bottom) . No calcifications or osteogenic formation was noted in all analyzed sections. To address cardiomyogenic conversion rates, a separate quantitative histological analysis was performed in five group A dogs and three group B dogs (Fig. 6) Table 1 shows baseline LV morphology and function before and after cell injections. In noninfarcted hearts, LV area shortening was 72 Ϯ 4% and regional wall thickening was 76 Ϯ 5%. After coronary ligation and before cell injections, LV dysfunction was confirmed by the stable reduction of percent area shortening and reduced percent wall thickening of the infarcted region (Fig. 7) . The reduction in LV function as compared with baseline was similar in both groups ( Table 1) . Injections of untreated MSCs were not associated with any significant changes in both area shortening and regional wall thickening. In contrast, in dogs with pretreated MSCs, cell injections were associated with a significant increase in both area shortening and regional wall thickening observed at 4 wk and persisted up to 12 wk after the injection, suggesting a higher degree of functional recovery after the injection of cardiac-specified MSCs. Finally, wall motion score index decreased significantly in group A as compared with group B dogs ( Table 1) . No relationship was noted between the functional improvement and proportion of cells expressing cardiac myosin in tissue sections.
DISCUSSION
The results of the present study can be summarized as follows: 1) pretransplantational treatment of adult autologous MSCs cells using appropriate biological growth factors is feasible and leads to cardiomyogenic specification and 2) biological and functional effects upon cardiac regeneration of chronically infarcted myocardium were superior after myocardial injections of prespecified MSCs as compared with unmodified cells.
Cardiomyogenic specification of bone marrow MSCs. An immediate challenge in cardiac regeneration is to devise a strategy that leads to a reproducible degree of cardiac differentiation. MSCs have pluripotent characteristics, can contribute to the development of most somatic tissues, and may represent an optimal cell type for this purpose. They can undergo cardiac differentiation after injection into the normal myocardium (8) . However, the use of unmodified bone marrow cells in experimental myocardial infarction models is controversial (5, 10, 21, 22, 31, 32). In the swine model of myocardial ischemia-reperfusion injury, allogenic mesenchymal bone marrow cells appeared to contribute to the neovascularization and myogenesis and led only transiently to improved cardiac performance (21) . On the other hand, in a dog model of myocardial infarction, injection of the same cells led to a functional improvement in parallel to increased capillary density despite the absence of cardiac markers in DiI-labeled cells (22) . In addition, in this study, follow-up was limited only to 30 days. Other investigators (5, 10, 31, 32) suggested that unmodified mononuclear or MSCs injected into the chronically infarcted areas do not differentiate into the cardiomyocyte lineage and may differentiate into fibroblasts (31) or form intramyocardial calcifications (32) . Increasing controversy regarding the ability of bone marrow progenitors to transdifferentiate in vivo into cardiomyocyte-like cells led to the suggestion that alternative strategies with coaxing the cells toward the cardiac lineage or addressing critical molecular pathways of cardiac differentiation should be investigated as an approach to increase the reproducibility of cardiac differentiation (6, 16) . The concept of ex vivo pretransplantational myogenic specification was previously attempted using 5Ј-azacytidine (29, 30) . However, 5Ј-azacytidine as an inductive chemical compound may not be suitable for clinical use. It acts randomly on the genome such that myogenic differentiation is observed only in 30% of the treated cells (30) and the possibility of generating undesirable cell type remains high.
Biological cardiomyogenic signals and specification of adult bone marrow progenitors. We have taken clues from early embryonic heart development to test whether growth factors involved in early cardiomyogenesis have the ability to drive MSCs toward the cardiomyogenic cell lineage. During chick, amphibian, or mammalian embryonic development, signals emanating from the overlying anterior endoderm are required for the specification and stabilization of the underlying mesoderm to a cardiogenic cell lineage (1, 3, 7, 26) . Moreover, recent reports indicate that coculture of human embryonic stem cells with mouse visceral endoderm-like cells resulted in a high degree of conversion of human embryonic stem cells into beating cardiomyocytes (20) . While the ideal composition of the growth factor "cocktail" secreted by the endoderm to induce cells to a cardiogenic lineage is yet to be determined, several factors secreted by anterior endodermal cells, including BMP-2 and basic FGF, have been implicated as critical components of this early cardiomyogenic inductive signaling (14, 20, 26) . Nevertheless, it remains a challenge to apply knowledge obtained from embryonic cells to adult stem cells. Therefore, in the present study, we tested the hypothesis that cardiomyogenic growth factors may induce cardiac specification of adult bone marrow MSCs ex vivo. The pretreated cells retained their morphological appearance of typical MSCs, but successful cardiac myogenic specification was confirmed by the presence of the early myogenic and cardiac markers desmin, MEF-2, and Nkx-2.5. Yet, to enhance the engraftment of the specified cells after injections, the course of cardiac differentiation was controlled such that specified cells expressed early cardiac muscle markers and remained negative for the MHC protein, an adult marker of fully differentiated muscle cells.
To mimic the clinical setting of chronically dysfunctional myocardium, further cardiac myogenic differentiation was tested in a dog model of myocardial infarction with cell injections performed Ͼ8 wk after ligation. Myocyte-like differentiation of specified MSCs was observed as early as 2 wk after the injections. The new expression of cardiac myocyte specific markers was observed in the later stages and persisted until the end of the 12-wk follow-up. Of note, injected cells formed new islands of cardiac-like cells even within the infarcted tissue and showed morphology similar to myocytes in the surrounding area, including presence of striations, parallel orientation, and expression of connexin 43. It should be noted that despite the faint expression of alkaline phosphatase in vitro, no calcifications were observed in vivo after injection of pretreated cells. In contrast, density of DiI-labeled cells colocalizing with cardiac myosin was higher after pretreatment with growth factors as compared with nonmodified bone marrow MSCs. Recent data of Mangi et al. (10) suggested that cardiac differentiation and repair mediated by MSCs in acutely injured myocardium can be enhanced by enhancing Aktmediated survival signaling. Accordingly, to inhibit pharmacological apoptosis, caspase-8 inhibitor was added to the cell suspension before myocardial injections in all animals. Nevertheless, in our large animal chronic model of the myocardial infarction, the extent of cardiomyogenic differentiation as evidenced from proportion of cardiac myosin in DiI-labeled cells was lower in tissue sections of hearts from dogs who received nonmodified MSCs despite the similar extent of pharmacological inhibition of apoptosis. Taken together, these data show for the first time that ex vivo specification of bone marrow mesenchymal progenitors using cardiomyogenic growth factors is feasible and may lead to a greater colocalization with cardiac markers as compared with injection of nonmodified MSCs.
As to the secondary objective, regional contractility was improved at the site of injections with specified MSCs. Though it is attractive to hypothesize that the improved regional function was a direct result of the regeneration of cardiomyocytes, the conversion rates remain low and the exact mechanism responsible for the functional improvement remains to be investigated. Alternative mechanisms may include paracrine effects of specified cells on the neighboring myocytes and the positive effects on angiogenesis or cell fusion. Furthermore, other, yet unknown effects related to the pharmacological pretreatment should be considered. Invasive monitoring of global and regional LV performance and/or MRI and perfusion studies in parallel to cell tracking may provide additional insights into the functional effects of the specified MSCs.
Limitations. Several limitations should be acknowledged. First, limited functional improvement was seen after injection of nonmodified MSCs. Besides the controversy related to biological and functional effects of nonmodified MSCs (21, 22, 31, 32) , this can be related to differences in the design of the current and previous studies, animal models, extent of LV dysfunction, and cell source. In previous studies, functional improvement was associated with allogenic source in larger infarctions and cells were injected earlier after myocardial infarction as compared with injections Ͼ8 wk after the coronary ligation in our study. Note also that in our study, caspase-8 inhibitor was added to both modified and nonmodified MSCs to prevent apoptotic cell death. Nevertheless, it was added at low doses and did not modify the functional response in the chronically infracted myocardium. Second, despite the functional improvement after injections of modified MSCs paralleled by colocalization with cardiac markers and striations, paracrine effects of modified MSCs ought to be considered. Likewise, despite the presence of gap junction proteins, full functional integration and excitation-contraction coupling of the implanted cells within the hosting myocardium need to be demonstrated. Thus passive changes in the wall composition and/or paracrine mechanisms cannot be excluded as potential mechanisms underlying the functional improvement. Third, only one cell type was injected, which may be suboptimal to achieve long-term sustainable cardiac repair. However, it should be noted that treatment with growth factors led to cardiac lineage cell specification typically found in early cardiac embryogenesis. In analogy to cardiac embryogenesis, such cells may hypothetically recruit other cell types needed for myocardial repair. In fact, injected modified cells were identified, albeit at very low frequency, in vascular-like structures, suggesting the potential of these cells to contribute to repair of other myocardial structural components. On the other hand, Values are means Ϯ SE. Group A, dogs with treated bone marrow mesenchymal cells followed with echocardiography (n ϭ 7). Group B, dogs with nontreated mesenchymal cells followed with echocardiography (n ϭ 4). HR, heart rate; LV, left ventricular; LVEDD, LV end-diastolic dimension; LVESD, LV end-systolic dimension; FS, fractional shortening. *P Ͻ 0.05 vs. baseline (BL) 1 and 2 by ANOVA; †P Ͻ 0.05 vs. Group B. BL 1, 3 wk before cell injection; BL 2, immediately before cell injection; FU 12 wk, follow-up at 12 wk. further studies are needed to address whether preconditioning of MSCs toward multiple tissue lineages may promote more complete regeneration of cardiac tissue. Fourth, in our study, the fate and conversion rates of injected cells were followed by histochemistry. DiI is characterized by a "punctuated" cytoplasmic staining and is widely used to track the fate of cells. However, this technique is limited to a single time point, and cell counting from tissue section is exposed to a number of limiting factors like section orientations compromising the quantitative histological analysis. These factors include DiI turnover in dying or multiplying cells, feasibility to analyze number of section in a large animal model, etc. Thus additional studies are needed to quantify the engraftment rates and survival of modified cells using dedicated cell tracking imaging techniques with MRI-compatible labeling or molecular tagging. Metabolic and electromechanical characteristics of the newly formed cardiac myocyte-like cells were not addressed in this study. Finally, the major limitation of any cell transplantation techniques is cell loss after injection. In addition to using antiapoptotic treatment, improved delivery strategies, for instance with the use of matrix-based delivery (33) , should be explored to maximize engraftment and in vivo differentiation.
Summary. In the present study, we succeeded to demonstrate that ex vivo treatment with inductive growth factors is feasible in a large animal model and leads to cardiac specification of adult MSCs and their cardiac myocyte-like differentiation after injections into the chronically infarcted myocardium associated with superior functional effects. Thus the pretransplantational cardiac specification of autologous MSCs can be tested as a new strategy to achieve a reproducible degree of cardiac differentiation of the MSCs.
